22 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
13
Discovery of KDM5A inhibitors: Homology modeling, virtual screening and structure-activity relationship analysis.

Sichuan University
78
Recent Progress in Histone Demethylase Inhibitors.

University of Oxford
34
Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate Derivatives.

Glaxosmithkline
36
Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives.

Glaxosmithkline
31
Oncoepigenomics: making histone lysine methylation count.

TBA
10
Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases.

University of Oxford
39
Inhibitors of histone demethylases.

University of Copenhagen
2
Discovery of a first-in-class PROTAC degrader of histone lysine demethylase KDM4.

Shanghai Institute of Materia Medica
4
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response.

GlaxoSmithKline R&D
26
5-Substituted Pyridine-2,4-dicarboxylate Derivatives Have Potential for Selective Inhibition of Human Jumonji-C Domain-Containing Protein 5.

University of Oxford
43
Pharmacological inhibition of KDM5A for cancer treatment.

Ningbo University
34
Targeting histone demethylase KDM5B for cancer treatment.

Zhengzhou University
91
Inhibition of AlkB Nucleic Acid Demethylases: Promising New Epigenetic Targets.

University College London
17
Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors.

University of Oxford
44
Recent Advances with KDM4 Inhibitors and Potential Applications.

St. Jude Children'S Research Hospital
27
Enhanced Properties of a Benzimidazole Benzylpyrazole Lysine Demethylase Inhibitor: Mechanism-of-Action, Binding Site Analysis, and Activity in Cellular Models of Prostate Cancer.

Max Delbruck Center
38
Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor.

University of Oxford
9
Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities.

Sapienza University of Rome
35
Structure-based design and discovery of potent and selective KDM5 inhibitors.

Celgene
12
Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors

Merck Sharp & Dohme
2
X-ray structures of Torpedo californica acetylcholinesterase complexed with (+)-huperzine A and (-)-huperzine B: structural evidence for an active site rearrangement.

Weizmann Institute of Science